| BRAF mutation predicts sensitivity to MEK inhibition DB Solit, LA Garraway, CA Pratilas, A Sawai, G Getz, A Basso, Q Ye, ... Nature 439 (7074), 358-362, 2006 | 1535 | 2006 |
| V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway CA Pratilas, BS Taylor, Q Ye, A Viale, C Sander, DB Solit, N Rosen Proceedings of the National Academy of Sciences 106 (11), 4519-4524, 2009 | 655 | 2009 |
| Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ... Cancer cell 22 (5), 668-682, 2012 | 589 | 2012 |
| The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner EW Joseph, CA Pratilas, PI Poulikakos, M Tadi, W Wang, BS Taylor, ... Proceedings of the National Academy of Sciences 107 (33), 14903-14908, 2010 | 504 | 2010 |
| Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence MH Nissan, CA Pratilas, AM Jones, R Ramirez, H Won, C Liu, S Tiwari, ... Cancer research 74 (8), 2340-2350, 2014 | 347 | 2014 |
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors D Ercan, C Xu, M Yanagita, CS Monast, CA Pratilas, J Montero, ... Cancer discovery 2 (10), 934-947, 2012 | 326 | 2012 |
| Genomic and biological characterization of exon 4 KRAS mutations in human cancer M Janakiraman, E Vakiani, Z Zeng, CA Pratilas, BS Taylor, D Chitale, ... Cancer research 70 (14), 5901-5911, 2010 | 307 | 2010 |
| Genetic predictors of MEK dependence in non–small cell lung cancer CA Pratilas, AJ Hanrahan, E Halilovic, Y Persaud, J Soh, D Chitale, ... Cancer research 68 (22), 9375-9383, 2008 | 275 | 2008 |
| Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) JR Dry, S Pavey, CA Pratilas, C Harbron, S Runswick, D Hodgson, ... Cancer research 70 (6), 2264-2273, 2010 | 264 | 2010 |
| Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer EM Tricker, C Xu, S Uddin, M Capelletti, D Ercan, A Ogino, CA Pratilas, ... Cancer discovery 5 (9), 960-971, 2015 | 234 | 2015 |
| Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF F Xing, Y Persaud, CA Pratilas, BS Taylor, M Janakiraman, QB She, ... Oncogene 31 (4), 446-457, 2012 | 230 | 2012 |
| Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response CA Pratilas, DB Solit Clinical Cancer Research 16 (13), 3329-3334, 2010 | 228 | 2010 |
| Models from experiments: combinatorial drug perturbations of cancer cells S Nelander, W Wang, B Nilsson, QB She, C Pratilas, N Rosen, ... Molecular systems biology 4 (1), 216, 2008 | 210 | 2008 |
| New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as … ZQ Yang, X Geng, D Solit, CA Pratilas, N Rosen, SJ Danishefsky Journal of the American Chemical Society 126 (25), 7881-7889, 2004 | 206 | 2004 |
| Perturbation biology: inferring signaling networks in cellular systems EJ Molinelli, A Korkut, W Wang, ML Miller, NP Gauthier, X Jing, P Kaushik, ... PLoS computational biology 9 (12), e1003290, 2013 | 163 | 2013 |
| BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines R Leboeuf, JE Baumgartner, M Benezra, R Malaguarnera, D Solit, ... The Journal of Clinical Endocrinology & Metabolism 93 (6), 2194-2201, 2008 | 133 | 2008 |
| Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells A Korkut, W Wang, E Demir, BA Aksoy, X Jing, EJ Molinelli, Ö Babur, ... Elife 4, e04640, 2015 | 117 | 2015 |
| BRAF mutations and the utility of RAF and MEK inhibitors in primary brain tumors KC Schreck, SA Grossman, CA Pratilas Cancers 11 (9), 1262, 2019 | 115 | 2019 |
| Eosinophilic solid and cystic (ESC) renal cell carcinomas harbor TSC mutations: molecular analysis supports an expanding clinicopathologic spectrum DN Palsgrove, Y Li, CA Pratilas, MT Lin, A Pallavajjalla, C Gocke, ... The American journal of surgical pathology 42 (9), 1166-1181, 2018 | 114 | 2018 |
| The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling T Okada, S Sinha, I Esposito, G Schiavon, MA López-Lago, W Su, ... Nature cell biology 17 (1), 81-94, 2015 | 113 | 2015 |
Neal RosenProfessor of Pharmacology, Memorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
